Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials

BACKGROUND: Recent studies showed inconsistent results of bevacizumab combined with chemotherapy vs single-agent therapy in terms of their safety and efficacy for the treatment of recurrent glioblastoma. Therefore, we performed a meta-analysis to explore the value of bevacizumab combined with chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhouqing, Xu, Na, Zhao, Chongshun, Xue, Tao, Wu, Xin, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061394/
https://www.ncbi.nlm.nih.gov/pubmed/30087578
http://dx.doi.org/10.2147/CMAR.S173323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061394/
https://www.ncbi.nlm.nih.gov/pubmed/30087578
http://dx.doi.org/10.2147/CMAR.S173323

Ejemplares similares